Doximity Expands AI Capabilities with Acquisition of Pathway

Published: 05 Sep 2025

Author: Precedence Research

Share :

A leading health-tech company, Doximity, Inc., acquires Pathway Medical Inc. to extend its Artificial Intelligence capabilities in healthcare by offering AI tools for doctors at free of cost. According to the company's revelations, the transaction closed at USD 26 million and up to USD 37 million in additional equity grants. Pathway claims to have vast datasets in the medical sector, in a structured format compliant with all relevant guidelines, drugs, and landmark trials across the most prominent domains of the medical field.

Jeff Tangney, a co-founder and CEO of Doximity said, “What makes it powerful is its cross-linked structure that lets AI quickly get accurate answers for doctors. It's much more than an LLM (large language model). It understands complex drug interactions and scores the strength of medical evidence, such as weighing a validated clinical trial more than a case study.

The engineering team at Doximity has formed a partnership with Pathway to leverage their dataset and its AI capabilities, including the free Doximity GPT product. It is a specialized tool that helps doctors manage time-consuming administrative tasks, such as drafting and faxing preauthorization and appeal letters to insurers. The company is further testing combined products with thousands of physicians' beta testers.

Doctors utilize the Pathway’s AI-based clinical reference tool to ask questions about care guidelines, approved drugs, and clinical trials on drug interactions. The Pathway’s AI model is built using the best datasets in the medical sector, offering the best possible solutions at a new level.

Pathway is a seven-year-old startup based in Montreal, with physicians comprising the majority of its team members. Mr. Tangney told investors. 
“From a post-doc program at the prestigious Mila AI Institute, they founded Pathway five years before ChatGPT even existed to help answer the ICU bedside questions they faced every day."  

The model presented by the Pathway has outperformed other models with clinical accuracy and recorded scores with 96% on the U.S. medical Licensing examination benchmark, the companies said while talking to the press release. Pathway has many users worldwide, with thousands paying nearly USD 300 per year for the premium version they offer. In a nutshell, the acquisition of Pathway Medical shows a strategic move to leverage AI capabilities at its highest potential.